Elacestrant trials for HER2-negative Breast Cancer

All Elacestrant trials · All HER2-negative Breast Cancer trials

Phase breakdown

Recruiting trials studying Elacestrant for HER2-negative Breast Cancer

• BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors
  NCT06120283 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 62 locations
• ERADICATE: A Phase Ib/II Study of Elacestrant Plus Trastuzumab Deruxtecan in Patients With CDK4/6 Inhibitor and Endocrine-resistant HR+/HER2-low or HER2-ultralow Metastatic Breast Cancer
  NCT07198724 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Elacestrant + Everolimus in Patients ER+/HER2-, ESR1mut, Advanced Breast Cancer Progressing to ET and CDK4/6i.
  NCT06382948 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 104 locations
• Elacestrant With/Without Triptorelin in Premenopausal Women With Luminal Breast Cancer
  NCT05982093 · Phase: Phase 2 · Ages: 35 Years and older · Sex: Female · 15 locations
• Elacestrant for Treating ER+/HER2- Breast Cancer Patients With ctDNA Relapse (TREAT ctDNA)
  NCT05512364 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 112 locations

Common questions

How many trials study Elacestrant for HER2-negative Breast Cancer?

5 recruiting trials.

Is this list complete?

No. For the full record, search ClinicalTrials.gov.